Development of Augmented Leukemia/Lymphoma-Specific T-Cell Immunotherapy for Deployment with Haploidentical Hematopoietic Progenitor-Cell Transplant

Abstract

This project develops novel immune-based therapies to target childhood leukemia. By combining gene therapy with T-cell therapy we have developed new biologic agents that specifically recognize CD19 molecule on the cell surface of B-cell acute lymphoblastic leukemia (B-ALL). To translate this approach to the clinic we have adapted the Sleeping Beauty (SB) transposon/transposase system to express a CD19-specific chimeric antigen receptor (CAR). T cells that have undergone transposition express the CAR and therefore redirected specificity for CD19. To selectively propagate CD19-specific T cells to clinically-meaningful numbers we have developed artificial antigen presenting cells (aAPC) by expressing CD19 molecule and desired co-stimulatory molecules on K562 cells. Thus, by combining SB transposition and aAPC, we can harness gene therapy and T-cell therapy to develop targeted treatment for B-ALL.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
May 01, 2010
Accession Number
ADA625280

Entities

People

  • Laurence Cooper

Organizations

  • The University of Texas MD Anderson Cancer Center

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Cancer
  • Cells
  • Department Of Defense
  • Deployment
  • Electronic Mail
  • Immunotherapy
  • Leukemia
  • Lymphocytes
  • Molecules
  • Neoplasms
  • Stem Cells
  • Therapy
  • Transplants

Fields of Study

  • Biology
  • Medicine

Readers

  • Immunology
  • Oncology (Cancer Research).

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech